Sep 12, 2017 - Journal of Cancer Therapy, 2017, 8, 827-837 ... 2Department of Medical Oncology, Okayama Rosai Hospital, Okayama, Japan. Abstract.
OncoTargets and Therapy 2016:9 705â709. OncoTargets ... standard of care treatment in the metastatic setting, and it is associated with modest response and ...
In: The Clinical Handbook for the Management of Mood Disorders edited by John
Mann, ...... The Oxford Handbook of Event-Related Potential Components.
Abstract. Background: Cutaneous adverse events associated with the use of epidermal growth factor receptor inhibitors, such as cetuximab are relatively ...
Jul 22, 2009 - Clinical Predictors of Severe Cetuximab-Induced. Rash: Observations from 933 Patients. Enrolled in North Central Cancer Treatment.
Andrew C. Heath1,William Howells1, Katherine M. Kirk3, Pamela A.F. Madden1, Kathleen K. ...... Martin, N.G., Eaves, L.J., Heath, A.C., Jardine, R., Feingold, L.,.
Terman, Michael; Amira, Leora; Terman, Jiuan Su; Ross, Donald C. The American Journal of Psychiatry; Nov 1996; 153, 11; Research Library pg. 1423 ...
24 dengue, and 130 OFI), we identified absence of rashes, no leukopenia, and no ... to distinguish influenza from dengue using rash, leukopenia, and marked.
Apr 10, 2017 - Drug Development Unit, The Institute of Cancer Research and The Royal ... Princess Margaret Cancer Centre, University Health Network, ...
cal Research, Manhasset, New York, USA; Albert Einstein College of Medi- cine, Bronx, New ...... 2012,29 Diaz 2013,49 Albert 2011,44 Clemmen- sen 201268: ...
May 31, 2018 - Medical Foundation (CIRPD1D0031). ..... weber syndrome, with a review of treatments for diffuse and .... ated with Sturge-Weber syndrome.
italics) in either or both (good response and not good response) groups respectively: (A) Clinical variables: 145.8 (93.84) and 385.5 (364.66) days for duration of ...
May 31, 2018 - 117: 1630â1637. https://doi.org/10.1016/j.ophtha.2009.12.033 PMID: 20417564. 10. Cerman E, Cekic O Clinical use of photodynamic therapy ...
options available for MS management, screening potential candidates for different therapeutic ... Multiple Sclerosis Treatment (CATEM) of the Neurology.
Jul 12, 2010 - the role of PTEN loss of expression in head and neck squamous cell carcinoma ... cells, cetuximab keeps full ability to inhibit EGFR-dependent.
Aug 21, 2013 - All the lung cancer markers and methods are patented, and the lung cancer test is under the development in Quest Diagnostics. This does not.
measured in 2 kg of produce collected randomly, kept in good physi- ...... nta n°33. Santiago: Ministerio de Salud de Chile; 2010b. in: http://webhosting.
Jun 3, 2015 - Taylor & Francis makes every effort to ensure the accuracy of all the information .... Health, Redwood City, CA) recurrence score to make treat-.
Jun 4, 2011 - Western Hospital, Swindon, UK [34]); H Wasan (Hammersmith Hospital,. London, UK [34]); M Tighe, S Falk (Mu
Cushing1 and Dan- dy2 initially described subtotal and gross-total removal ..... torical Review of a Century of Operative Series. Neu- rosurg Quart 1991;1:2-18. 4.
Although smoking is a recognized risk factor for atheros- clerotic disease, regarding acute myocardial infarction, in- farction smoking patients are, on average, ...
ABSTRACT. Research on determinants of ECT seizure threshold is inadequate. In view of differences in. ECT populations and confounding factors, there is a ...
Nov 2, 2016 - Children's Memorial Health Institute, Warsaw, Poland, 3 Department of Neonatology, The Holy Family. Hospital, Warsaw, Poland.
Clinical predictors of response to cetuximab ... - Semantic Scholar
advanced colorectal cancers are likely to benefit from cetuximab- chemotherapy. Design Retrospective review. Setting Oncology unit in a university teaching ...
O R I G I N A L A R T I C L E
Ada TW Ma Brigette BY Ma Kenny IK Lei Frankie KF Mo Anthony TC Chan
Clinical predictors of response to cetuximabchemotherapy in metastatic colorectal cancer
馬天慧 馬碧如 李英傑 巫國輝 陳德章
Objective To identify clinical markers to predict which patients with advanced colorectal cancers are likely to benefit from cetuximabchemotherapy.
Design Retrospective review.
Setting Oncology unit in a university teaching hospital in Hong Kong.
Patients A total of 102 patients with metastatic colorectal cancer treated with cetuximab-chemotherapy.
Main outcome measures Correlation of multiple potential clinical predictive factors with tumour response to cetuximab-chemotherapy.
Results The objective response rates to cetuximab plus chemotherapy were 53% in patients receiving first-line treatment and 17% in previously treated patients. The univariate analysis indicated that fewer prior lines of chemotherapy (odds ratio=0.36; 95% confidence interval, 0.21-0.63; P
